MEN2312

Phase 1Small molecule

SStemline Therapeutics, Inc.

MEN2312 is one of 38 small molecule programs targeting Advanced Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Breast CancerRecruiting

Advanced Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

39 competitors in Advanced Breast Cancer

#DrugCompanyPhaseTrials

Piqray

Novartis

Approved

2 2

Faslodex

FFresenius Kabi USA, LLC

Approved

6 3

Kisqali

Novartis

Phase 3

3 4

Ibrance

Pfizer

Phase 3

3 5

Verzenio

Eli Lilly

Phase 3

2 6

Femara

Novartis

Phase 3

2 7

Afinitor

Novartis

Phase 3

1 8

Aromasin

Pfizer

Phase 3

1 9

Perjeta

Roche

Phase 3

1 10

Orserdu

SStemline Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Advanced Breast Cancer

NCT06638307

Clinical

Trials by Indication[1]

Advanced Breast Cancer1 trial

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

Recruiting·SStemline Therapeutics, Inc.·Phase 1·NCT06638307·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MEN2312. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEN2312 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEN2312. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stemline Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SStemline Therapeutics, Inc.

MEN2312

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News